Category Health & IP

Alto Funcionário Discute Sobre Renúncia Ao Seu Cargo Na ANVISA, No Brasil, Devido à Política Sobre Patentes

Luis Carlos Wanderley Lima, funcionário sênior responsável pela política brasileira que expressa a opinião do Ministério da Saúde no referente à análise de pedidos de patente que possam ocasionar um impacto na saúde pública, renunciou recentemente em protesto contra as modificações na mencionada política. Em uma sessão de perguntas e respostas com a Intellectual Property Watch, ele conversou com relação a sua decisão.

Top Official Discusses Resignation From Brazil’s ANVISA Over Patent Policy

Luis Carlos Wanderly Lima, a senior official responsible for Brazil’s policy of giving a voice to its health ministry in the examination of patent applications with potential impact on public health, recently resigned in protest about changes to the policy. In a Q&A with Intellectual Property Watch, he discussed his decision.

Myriad Outcome: Winds Shift Again For Gene Patenting In The US

In a long-awaited decision, a United States federal appeals court has decided that US companies can patent breast cancer genes, reversing a previous ruling. The decision was not unanimous, with one of the three judges dissenting. But despite the attention the case has received, the ruling may have little impact on the biotechnology industry, according to analysts.

EU-India Agreement In WTO Dispute Raises Bar For EU Drug Seizures

India and the European Union announced a written agreement yesterday that puts more conditions on EU customs authorities before they can stop shipments of generic pharmaceuticals passing through Europe. No longer is the existence of an EU patent on passing generics sufficient cause to stop shipments. The agreement suspends a World Trade Organization dispute started by India last year.

Corporate Self-Interest And Strategic Choices: Gilead Licenses To Medicines Patent Pool

Gilead's recently announced ARV licenses to the Medicines Patent Pool, although positive in some respects, still unreasonably limit the geographical access of key middle-income countries and restrict the sourcing of APIs and products to Indian companies, meaning that both generics companies and excluded countries will need to make strategic decisions to bypass the defects in the licenses, writes Brook Baker.

Parliament Study: ACTA Not Fully In Line With EU Rules

The Anti-Counterfeiting Trade Agreement (ACTA) under negotiation by a group of countries including those in the European Union is more ambitious than current EU law and risks problems for access to medicines, concluded a recent study commissioned by the European Parliament Committee on International Trade. But the study stops short of calling for a flat rejection of the agreement.

Kenya Opens Region’s Door To GM Maize

In the face of a severe food shortage, Kenya's Cabinet has approved imports of genetically modified maize, though it has drawn the line on use of GM maize as seeds, a regional newspaper reports.

Interview With Chief Judge Paul R. Michel On US Patent Reform

Chief Judge Paul R. Michel (Ret.), of the U.S. Court of Appeals for the Federal Circuit, saw hundreds of patent cases during his distinguished career and has a unique position from which to view and offer advice on efforts in the US Senate and House of Representatives to agree on changes to domestic patent law. Intellectual Property Watch recently had the opportunity to interview Judge Michel on prospects for substantive patent reform in the US, the effect on future cases involving domestic and foreign patents, likely constitutional challenges, and the "non-problem" of non-practicing entities.

Neglected Diseases R&D Financing Proposals Shaping Up At WHO

Global public health experts in charge of exploring ways to finance R&D on diseases endemic in developing countries last week provided a preliminary summary of assessments on proposals provided by various stakeholders. They also made recommendations to establish global mechanisms, including a binding global instrument for R&D and innovation for health.

WHO Enters Next Phase Of Global Plan To Increase Flu Vaccine Production

The World Health Organization will be entering a new phase of its global action plan for influenza vaccines, a WHO representative told reporters today. The goals of the first phase of the programme should be furthered but with more attention given to the local health and policy environment, WHO said.